FY2027 Earnings Estimate for BPMC Issued By Leerink Partnrs

Blueprint Medicines Co. (NASDAQ:BPMC) – Equities researchers at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for shares of Blueprint Medicines in a research note issued to investors on Tuesday, January 14th. Leerink Partnrs analyst A. Berens anticipates that the biotechnology company will earn $4.98 per share for the year. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.68) per share.

Several other research analysts have also weighed in on the company. Wedbush reiterated an “outperform” rating and set a $124.00 target price (down from $135.00) on shares of Blueprint Medicines in a report on Monday. JPMorgan Chase & Co. initiated coverage on shares of Blueprint Medicines in a research note on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, November 15th. Finally, StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Blueprint Medicines has an average rating of “Moderate Buy” and an average target price of $122.72.

Blueprint Medicines Trading Down 0.9 %

BPMC opened at $103.95 on Thursday. The firm’s fifty day moving average is $93.85 and its two-hundred day moving average is $95.36. The firm has a market cap of $6.60 billion, a PE ratio of -49.27 and a beta of 0.61. Blueprint Medicines has a twelve month low of $72.24 and a twelve month high of $121.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32.

Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The company’s revenue for the quarter was up 126.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.20) EPS.

Hedge Funds Weigh In On Blueprint Medicines

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP increased its stake in Blueprint Medicines by 22.5% in the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company’s stock valued at $366,726,000 after acquiring an additional 729,055 shares during the last quarter. Millennium Management LLC lifted its position in shares of Blueprint Medicines by 540.0% during the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company’s stock worth $67,646,000 after buying an additional 529,566 shares during the last quarter. 1832 Asset Management L.P. boosted its stake in Blueprint Medicines by 200,159.4% in the second quarter. 1832 Asset Management L.P. now owns 502,651 shares of the biotechnology company’s stock valued at $54,176,000 after buying an additional 502,400 shares in the last quarter. State Street Corp grew its position in Blueprint Medicines by 16.2% in the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company’s stock valued at $255,827,000 after acquiring an additional 385,818 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of Blueprint Medicines by 161.1% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 496,087 shares of the biotechnology company’s stock valued at $45,888,000 after purchasing an additional 306,079 shares in the last quarter.

Insider Activity at Blueprint Medicines

In other news, CEO Kate Haviland sold 2,353 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $96.60, for a total value of $227,299.80. Following the completion of the sale, the chief executive officer now owns 150,824 shares of the company’s stock, valued at approximately $14,569,598.40. The trade was a 1.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total transaction of $216,257.40. Following the completion of the transaction, the chief operating officer now owns 71,657 shares in the company, valued at $6,814,580.70. This trade represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,970 shares of company stock worth $2,914,246 in the last ninety days. 4.21% of the stock is owned by company insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.